Table 2.

Summary of the primary and secondary endpoints in the study

Endpoints	PGATx (n=52)	TAU (n=48)	F value	p value
HAMD†	−16.1±6.8	−12.1±8.2	6.818	0.010
FIBSER†	−4.1±5.3	−1.6±5.9	4.989	0.028
PHQ-9†	−13.6±6.8	−9.8±7.8	6.656	0.011
PHQ-15†	−8.1±5.0	−6.4±6.8	2.055	0.155
CGI-S†	−3.3±1.4	−2.3±1.8	9.755	0.002
GAD-7†	−6.2±4.9	−4.1±4.7	4.696	0.033
SDS†	−9.9±7.8	−6.3±9.0	4.007	0.048
The proportion of patients showing 1 or 2 in the CGI-I score*,‡	37 (80.4)	28 (60.9)	-	0.66

Values are presented as mean±standard deviation or number (%).

PGATx, pharmacogenetic-based antidepressant treatment; TAU, treatment as usual; PHQ-9/15, Patient Health Questionnaire-9/15; CGI-S, Clinical Global Impression-Severity; GAD-7, General Anxiety Disorder-7; SDS, Sheehan Disability Scale.

^*Fisher’s exact test;

^†The change from baseline to the end of treatment;

^‡Proportion at the end of treatment.